National Biodefense Science Board. (2011). Challenges in the Use of Anthrax Vaccine Adsorbed (AVA) in the Pediatric Population as a Component of Post-Exposure Prophylaxis (PEP).
The Board explored challenges regarding Anthrax Vaccine Absorbed (AVA) and considered options for pre- and post-event research. AVA is not licensed for use in children and there is no clinical data on its use in pediatric populations for pre- or post-exposure prophylaxis in children. The Board recommended that HHS plan and conduct a pre-event research study.